ICON Public Limited (ICLR) 6-K 24 Jul 20 2020 Q2 Current report (foreign) Financial data

Cover

Cover	6 Months Ended
	Jun. 30, 2020
Cover [Abstract]
Document Type	6-K
Entity Registrant Name	ICON plc
Amendment Flag	false
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001060955
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets $ in Thousands	Jun. 30, 2020USD ($)shares	Dec. 31, 2019USD ($)shares
Current Assets:
Cash and cash equivalents	$ 592,100	$ 520,309
Available for sale investments	1,728	49,628
Accounts receivable, net of allowance for credit losses	473,020	527,708
Unbilled revenue	410,397	422,769
Other receivables	34,456	39,290
Prepayments and other current assets	38,108	41,517
Income taxes receivable	28,589	23,759
Total current assets	1,578,398	1,624,980
Other Assets:
Property, plant and equipment, net	162,552	165,087
Goodwill	901,245	883,170
Operating right-of-use assets	86,267	104,977
Other non-current assets	16,939	17,439
Non-current income taxes receivable	13,451	17,230
Non-current deferred tax asset	15,794	16,682
Investments in equity-long term	11,326	10,053
Intangible assets	72,748	67,894
Total Assets	2,858,720	2,907,512
Current Liabilities:
Accounts payable	32,722	24,050
Unearned revenue	393,217	366,988
Other liabilities	385,036	378,543
Income taxes payable	9,190	12,031
Current bank credit lines and loan facilities	349,828	349,640
Total current liabilities	1,169,993	1,131,252
Other Liabilities:
Non-current operating lease liabilities	63,974	76,593
Non-current other liabilities	21,662	17,512
Non-current government grants	792	813
Non-current income taxes payable	13,351	14,301
Non-current deferred tax liability	10,465	9,476
Commitments and contingencies	0	0
Total Liabilities	1,280,237	1,249,947
Shareholders' Equity:
Ordinary shares, par value 6 euro cents per share; 100,000,000 shares authorized, 52,508,751 shares issued and outstanding at March 31, 2020 and 53,622,206 shares issued and outstanding at December 31, 2019	4,569	4,635
Additional paid-in capital	592,500	577,961
Other undenominated capital	1,134	1,052
Accumulated other comprehensive income	(89,740)	(75,819)
Retained earnings	1,070,020	1,110,226
Total Shareholders' Equity	1,578,483	1,618,055
Redeemable noncontrolling interest	0	39,510
Total Shareholders' Equity and Redeemable Noncontrolling Interest	1,578,483	1,657,565
Total Liabilities and Shareholders' Equity and Redeemable Noncontrolling Interest	$ 2,858,720	$ 2,907,512
Ordinary shares, shares authorized (in shares) | shares	100,000,000	100,000,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - € / shares	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Ordinary shares, par value (in EUR cents per share)	€ 6	€ 6
Ordinary shares, shares authorized (in shares)	100,000,000	100,000,000
Ordinary shares, shares issued (in shares)	52,629,067	53,622,206
Ordinary shares, shares outstanding (in shares)	52,629,067	53,622,206

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenue	$ 620,228	$ 695,137	$ 1,335,330	$ 1,369,989
Costs and expenses:
Direct costs	445,833	490,656	951,126	966,153
Selling, general and administrative expense	83,499	83,203	170,695	165,115
Depreciation and amortization	15,858	15,188	32,180	30,685
Restructuring	18,089	0	18,089	0
Total costs and expenses	563,279	589,047	1,172,090	1,161,953
Income from operations	56,949	106,090	163,240	208,036
Interest income	441	1,780	2,250	3,525
Interest expense	(3,220)	(3,199)	(6,401)	(6,553)
Income before provision for income taxes	54,170	104,671	159,089	205,008
Provision for income taxes	(6,410)	(12,456)	(19,000)	(24,496)
Net income	47,760	92,215	140,089	180,512
Net income attributable to noncontrolling interest	0	(358)	(633)	(358)
Net income attributable to the Group	$ 47,760	$ 91,857	$ 139,456	$ 180,154
Net income per Ordinary Share attributable to the Group (note 10):
Basic (USD per share)	$ 0.91	$ 1.70	$ 2.55	$ 3.34
Diluted (USD per share)	$ 0.90	$ 1.69	$ 2.51	$ 3.31
Weighted average number of Ordinary Shares outstanding:
Basic (in shares)	52,570,104	53,957,446	52,959,229	53,901,427
Diluted (in shares)	53,028,567	54,449,117	53,691,138	54,355,705

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net income	$ 140,089	$ 180,512
Adjustments to reconcile net income to net cash provided by operating activities:
Loss on disposal of property, plant and equipment	95	29
Depreciation expense	22,643	22,916
Impairment of right-of-use assets	5,411	0
Reduction in carrying value of operating right-of-use assets	14,337	15,046
Amortization of intangibles	9,537	7,769
Amortization of government grants	(22)	(22)
Interest on short term investments	0	(538)
Interest on non-current operating lease liability	1,006	1,506
Realized gain on sale of short term investments	(232)	0
Loss/(gain) on re-measurement of financial assets	0	(500)
Stock compensation expense	13,186	12,834
Amortization of interest rate hedge	(482)	(464)
Amortization of financing costs	258	255
Deferred taxes	(2,613)	2,465
Changes in assets and liabilities:
Decrease/(increase) in accounts receivable	58,170	(9,285)
Decrease/(increase) in unbilled revenue	12,226	(124,158)
Decrease in other receivables	2,689	1,666
Decrease/(increase) in prepayments and other current assets	2,937	(2,946)
Decrease/(increase) in other non-current assets	486	(1,925)
Increase in unearned revenue	25,056	42,263
Decrease in other current liabilities	(33,507)	(10,581)
Decrease in operating lease liabilities	(15,416)	(16,724)
Increase in other non-current liabilities	2,355	147
Decrease in income taxes payable	(5,931)	(3,191)
Increase in accounts payable	8,370	295
Net cash provided by operating activities	260,648	117,369
Cash flows from investing activities:
Purchase of property, plant and equipment	(21,161)	(18,217)
Purchase of subsidiary undertakings	(47,367)	(81,631)
Cash acquired with subsidiary undertaking	10,170	8,405
Purchase of available for sale investments	0	(9,105)
Sale of available for sale investments	47,902	9,061
Purchase of investments in equity - long term	(1,273)	(3,305)
Net cash used in investing activities	(11,729)	(94,792)
Cash flows from financing activities:
Proceeds from exercise of equity compensation	1,461	17,054
Share issue costs	(6)	(6)
Repurchase of ordinary shares	(175,000)	(65,100)
Share repurchase costs	(140)	(52)
Net cash used in financing activities	(173,685)	(48,104)
Effect of exchange rate movements on cash	(3,443)	(116)
Net increase/(decrease) in cash and cash equivalents	71,791	(25,643)
Cash and cash equivalents at beginning of period	520,309	395,851
Cash and cash equivalents at end of period	$ 592,100	$ 370,208

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity and Comprehensive Income - 6 months ended Jun. 30, 2020 - USD ($) $ in Thousands	Total	Interest Rate Hedge	Cash Flow Hedge	Ordinary Shares	Additional Paid-in Capital	Other Undenominated Capital	Accumulated Other Comprehensive Income	Accumulated Other Comprehensive IncomeInterest Rate Hedge	Accumulated Other Comprehensive IncomeCash Flow Hedge	Retained Earnings	Redeemable Noncontrolling Interest
Beginning balance (in shares) at Dec. 31, 2019	53,622,206			53,622,206
Beginning balance at Dec. 31, 2019	$ 1,618,055			$ 4,635	$ 577,961	$ 1,052	$ (75,819)			$ 1,110,226
Comprehensive income:
Net income	139,456									139,456
Currency translation adjustment	(11,828)						(11,828)
Currency impact of long term funding (net of tax)	(1,002)						(1,002)
Transfer to realized capital gain	(232)						(232)
Amortization of interest rate hedge	(482)						(482)
Fair value of cash flow hedge (net of tax)		$ (760)	$ 383					$ (760)	$ 383
Total comprehensive income	125,535						(13,921)			139,456
Exercise of share options (in shares)				40,199
Exercise of share options	1,448			$ 3	1,445
Issue of restricted share units (in shares)				201,880
Issue of restricted share units	13			$ 13
Non-cash stock compensation expense	13,100				13,100
Share issuance costs	(6)				(6)
Share repurchase program (in shares)				(1,235,218)
Share repurchase program	(175,000)			$ (82)		82				(175,000)
Share repurchase costs	(140)									(140)
Noncontrolling interest adjustment to redemption amount	$ (4,522)									(4,522)
Ending balance (in shares) at Jun. 30, 2020	52,629,067			52,629,067
Ending balance at Jun. 30, 2020	$ 1,578,483			$ 4,569	$ 592,500	$ 1,134	$ (89,740)			$ 1,070,020
Beginning balance at Dec. 31, 2019	39,510										$ 39,510
Increase (Decrease) in Temporary Equity [Roll Forward]
Net income attributable to redeemable noncontrolling interest											633
Total comprehensive income											633
Noncontrolling interest adjustment to redemption amount											4,522
Exercise of call option on noncontrolling interest shares											(44,665)
Ending balance at Jun. 30, 2020	$ 0										$ 0

Basis of presentation

Basis of presentation	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation These condensed consolidated financial statements which have been prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”) have not been audited. The condensed consolidated financial statements reflect all adjustments, which are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented. The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the condensed consolidated financial statements. Actual results could differ from those estimates. The condensed consolidated financial statements should be read in conjunction with the accounting policies and notes to the consolidated financial statements included in ICON’s Form 20-F for the year ended December 31, 2019 (see note 2 - Significant accounting policies for impact of adoption of any new accounting standards). Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal period ending December 31, 2020.

Significant accounting policies

Significant accounting policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Significant accounting policies	Significant accounting policies Redeemable noncontrolling interests and equity On May 23, 2019, ICON acquired a majority ownership interest in MeDiNova. Included in the purchase agreement are put and call option arrangements with the noncontrolling interest holders that require (put option) or enable (call option) ICON to purchase the remaining minority ownership at a future date. The option is accounted for as temporary equity, which is presented separately as redeemable noncontrolling interest on the Consolidated Balance Sheet. This classification reflects the assessment that the instruments are contingently redeemable in accordance with ASC 480-10-S99 ' Distinguishing Liabilities from Equity '. Redeemable noncontrolling interests are accreted to their redemption value over the period from the date of issuance to the first date on which the option is exercisable. The change in the option's redemption value is recorded against retained earnings. In a computation of earnings per share, the accretion of redeemable noncontrolling interests to their redemption value is a reduction of net income attributable to the Group. Basic and diluted net income per ordinary share attributable to the Group includes the adjustment to reflect the accretion of the noncontrolling interest to its redemption value. On March 9, 2020 ICON exercised its option to call the outstanding shares in the noncontrolling interest to take 100% ownership of MeDiNova. On exercise of the call option, the noncontrolling interest is extinguished and a liability is recorded for the amount payable to the former noncontrolling interest holders. This liability was settled on July 17, 2020 for $43.9 million. Financial assets - credit losses On January 1, 2020, the Group adopted ASU 2016-13 'Measurement of Credit Losses on Financial Instruments (ASC 326)' , which significantly changes the way entities recognize impairment of many financial assets by requiring immediate recognition of estimated credit losses expected to occur over their remaining life. The update provides guidance on the measurement of credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The amendment replaces the current incurred loss impairment approach with a methodology to reflect expected credit losses and requires consideration of a broader range of reasonable and supportable information to explain credit loss estimates. The Group adopted ASC 326 using the modified retrospective method for all in scope financial assets. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 while prior period amounts continue to be reported in accordance with previously applicable GAAP. The impact of transitioning to the new standard at January 1, 2020 was immaterial and no adjustment was recorded to retained earnings for the cumulative effect of adopting ASC 326. On transition to ASC 326, the Group has revised the methodology to calculate the allowance for credit losses. The Group's estimate of expected credit losses considers historical credit loss information that is adjusted, where necessary, for current conditions and reasonable and supportable forecasts. Historical credit loss experience provides the basis for the estimation of expected credit losses. The Group's receivables and unbilled services are predominantly due from large and mid-tier pharmaceutical and biotechnology companies that share similar risk characteristics. The Group monitors their portfolio of receivables and unbilled services for any deterioration in current or expected credit quality (for example, expected delinquency level), and adjusts the allowance for credit losses as required. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in the Consolidated Statement of Operations. Losses are charged against the allowance when management believes the uncollectibility of a previously provisioned amount is confirmed. Leases The new leasing standard ( ASC 842 'Leases' ) was effective and adopted by ICON from January 1, 2019. ASC 842 ' Leases ' supersedes the requirements in ASC 840 'Leases' and requires that lessees recognize rights and obligations from virtually all leases (other than leases that meet the definition of a short-term lease) on their balance sheets as right-of-use assets with corresponding lease liabilities. The ASU also provides additional guidance on how to classify leases and how to determine the lease term for accounting purposes. ICON adopted the new standard under the cumulative effect adjustment approach There was no impact of adopting ASC 842 on opening retained earnings at January 1, 2019.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Revenue disaggregated by customer profile is as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Top client $ 74,932 $ 89,565 $ 156,199 $ 189,559 Clients 2-5 179,018 166,772 381,996 336,285 Clients 6-10 86,449 87,725 160,800 166,499 Clients 11-25 101,417 139,086 231,501 274,748 Other 178,412 211,989 404,834 402,898 Total $ 620,228 $ 695,137 $ 1,335,330 $ 1,369,989 Accounts receivables and unbilled revenue are as follows: June 30, 2020 December 31, 2019 (in thousands) Contract assets: Billed services (accounts receivable) $ 482,349 $ 535,088 Unbilled services (unbilled revenue) 410,397 422,769 Accounts receivable and unbilled revenue 892,746 957,857 Allowance for credit losses (9,329) — Allowance for doubtful debts — (7,380) Accounts receivable and unbilled revenue, net $ 883,417 $ 950,477 Unbilled services and unearned revenue or payments on account (contract assets and liabilities) were as follows: (in thousands, except percentages) June 30, 2020 December 31, 2019 $ Change % Change Unbilled services (unbilled revenue) $ 410,397 $ 422,769 $ (12,372) (2.9) % Unearned revenue (payments on account) (393,217) (366,988) (26,229) 7.1 % Net balance $ 17,180 $ 55,781 $ (38,601) (69.2) % Timing may differ between the satisfaction of performance obligations and the invoicing and collection of amounts related to our contracts with customers. We record assets for amounts related to performance obligations that are satisfied but not yet billed and/or collected. These assets are recorded as unbilled services and therefore contract assets rather than accounts receivables when receipt of the consideration is conditional on something other than the passage of time. Liabilities are recorded for amounts that are collected in advance of the satisfaction of performance obligations or billed in advance of the revenue being earned. Unbilled services/revenue balances arise where invoicing or billing is based on the timing of agreed milestones related to service contracts for clinical research. Contractual billing arrangements in respect of certain reimbursable expenses (principally investigators) require billing by the investigator to the Company prior to billing by the Company to the customer. As there is no contractual right to set-off between unbilled services (contract assets) and unearned revenue (contract liabilities), each are separately presented gross on the Consolidated Balance Sheet. Unbilled services as at June 30, 2020 decreased by $12.4 million as compared to December 31, 2019. Unearned revenue increased by $26.2 million over the same period resulting in a decrease of $38.6 million in the net balance of unbilled services and unearned revenue or payments on account between December 31, 2019 and June 30, 2020. These fluctuations are primarily due to timing of payments and invoicing related to the Group's clinical trial management contracts. Billings and payments are established by contractual provisions including predetermined payment schedules which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. Unbilled services arise from long-term contracts when a cost-based input method of revenue recognition is applied and revenue recognized exceeds the amount billed to the customer. The credit loss expense and allowance for credit losses recognized on the Group's receivables and unbilled services was de minimis for the six months ended June 30, 2020 and June 30, 2019.

Accounts receivable, unbilled r

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities)	Revenue Revenue disaggregated by customer profile is as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Top client $ 74,932 $ 89,565 $ 156,199 $ 189,559 Clients 2-5 179,018 166,772 381,996 336,285 Clients 6-10 86,449 87,725 160,800 166,499 Clients 11-25 101,417 139,086 231,501 274,748 Other 178,412 211,989 404,834 402,898 Total $ 620,228 $ 695,137 $ 1,335,330 $ 1,369,989 Accounts receivables and unbilled revenue are as follows: June 30, 2020 December 31, 2019 (in thousands) Contract assets: Billed services (accounts receivable) $ 482,349 $ 535,088 Unbilled services (unbilled revenue) 410,397 422,769 Accounts receivable and unbilled revenue 892,746 957,857 Allowance for credit losses (9,329) — Allowance for doubtful debts — (7,380) Accounts receivable and unbilled revenue, net $ 883,417 $ 950,477 Unbilled services and unearned revenue or payments on account (contract assets and liabilities) were as follows: (in thousands, except percentages) June 30, 2020 December 31, 2019 $ Change % Change Unbilled services (unbilled revenue) $ 410,397 $ 422,769 $ (12,372) (2.9) % Unearned revenue (payments on account) (393,217) (366,988) (26,229) 7.1 % Net balance $ 17,180 $ 55,781 $ (38,601) (69.2) % Timing may differ between the satisfaction of performance obligations and the invoicing and collection of amounts related to our contracts with customers. We record assets for amounts related to performance obligations that are satisfied but not yet billed and/or collected. These assets are recorded as unbilled services and therefore contract assets rather than accounts receivables when receipt of the consideration is conditional on something other than the passage of time. Liabilities are recorded for amounts that are collected in advance of the satisfaction of performance obligations or billed in advance of the revenue being earned. Unbilled services/revenue balances arise where invoicing or billing is based on the timing of agreed milestones related to service contracts for clinical research. Contractual billing arrangements in respect of certain reimbursable expenses (principally investigators) require billing by the investigator to the Company prior to billing by the Company to the customer. As there is no contractual right to set-off between unbilled services (contract assets) and unearned revenue (contract liabilities), each are separately presented gross on the Consolidated Balance Sheet. Unbilled services as at June 30, 2020 decreased by $12.4 million as compared to December 31, 2019. Unearned revenue increased by $26.2 million over the same period resulting in a decrease of $38.6 million in the net balance of unbilled services and unearned revenue or payments on account between December 31, 2019 and June 30, 2020. These fluctuations are primarily due to timing of payments and invoicing related to the Group's clinical trial management contracts. Billings and payments are established by contractual provisions including predetermined payment schedules which may or may not correspond to the timing of the transfer of control of the Company's services under the contract. Unbilled services arise from long-term contracts when a cost-based input method of revenue recognition is applied and revenue recognized exceeds the amount billed to the customer. The credit loss expense and allowance for credit losses recognized on the Group's receivables and unbilled services was de minimis for the six months ended June 30, 2020 and June 30, 2019.

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill Six Months Ended Year Ended June 30, 2020 December 31, 2019 (in thousands) Opening balance $ 883,170 $ 756,260 Current period acquisitions (Note 6) 27,304 126,932 Prior period acquisitions 123 — Foreign exchange movement (9,352) (22) Closing balance $ 901,245 $ 883,170

Business combinations

Business combinations	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Business combinations	Business combinations Acquisitions – MedPass Group ("MedPass") On January 22, 2020 a subsidiary of the Company, ICON Investments Limited acquired 100% of the equity share capital of the MedPass Group. MedPass is the leading European medical device CRO, regulatory and reimbursement consultancy, that specializes in medical device development and market access. The acquisition of MedPass further enhances ICON’s Medical Device and Diagnostic Research Services, through the addition of new regulatory and clinical capabilities in Europe. The integration of MedPass’s services brings noted expertise in complex class 3 medical devices, interventional cardiology and structural heart devices . The acquisition of MedPass has been accounted for as a business combination in accordance with ASC 805 ' Business Combinations' . The Company has made a provisional assessment of the fair value of assets acquired and liabilities assumed as at that date. January 22, 2020 (in thousands) Cash & cash equivalents $ 10,170 Property, plant and equipment 45 Operating right of use assets 539 Goodwill * 27,304 Customer relationships ** 11,725 Order backlog ** 2,883 Accounts receivable 3,033 Prepayments and other current assets 158 Accounts payable (368) Unearned revenue (989) Other liabilities (2,315) Current lease liabilities (219) Non-current lease liabilities (320) Non-current deferred tax liability (4,090) Net assets acquired $ 47,556 Cash outflows $ 46,992 Working capital adjustment payable 564 Contingent consideration *** — Total consideration $ 47,556 * Goodwill represents the acquisition of an established workforce that specializes in medical device development and market access. None of the goodwill recognized is expected to be deductible for income tax purposes. ** The Company has made an estimate of separate intangible assets acquired, being customer relationships and order book assets. This assessment will be finalized within 12 months of the date of acquisition. *** The fair value of the contingent consideration was estimated at the date of acquisition. Depending on performance of the company, the total consideration could increase by a maximum of $6.7 million in contingent consideration. At June 30, 2020, the fair value of this contingent consideration payable to MedPass is $Nil. Acquisitions – CRN Holdings LLC (trading as Symphony Clinical Research ("Symphony")) On September 24, 2019 a subsidiary of the Company, ICON Clinical Research LLC, acquired a 100% interest in Symphony. Symphony is a leading provider of at-home trial services and site support services. The acquisition of Symphony further enhances our site & patient services offering. The acquisition of Symphony has been accounted for as a business combination in accordance with ASC 805 ' Business Combinations' . The Company has made a provisional assessment of the fair value of assets acquired and liabilities assumed as at that date. September 24, 2019 (in thousands) Cash & cash equivalents $ 3,292 Property, plant and equipment 564 Operating right of use assets 820 Goodwill * 22,865 Customer relationships ** 8,159 Order backlog ** 2,163 Accounts receivable 4,544 Unbilled revenue 186 Prepayments and other current assets 181 Other receivables 6 Accounts payable (799) Unearned revenue (2,411) Other liabilities (933) Current lease liabilities (289) Non-current lease liabilities (531) Net assets acquired $ 37,817 Cash outflows $ 34,976 Working capital adjustment paid 341 Contingent consideration *** 2,500 Total consideration $ 37,817 * Goodwill represents the acquisition of an established workforce and the capability to provide at-home trial services and site support solutions. The full amount of the goodwill recognized is expected to be deductible for income tax purposes. ** The Company has made an estimate of separate intangible assets acquired, being customer relationships and order book assets. The fair value of Symphony’s intangible assets has been measured provisionally, pending receipt of a final independent valuation. This assessment will be finalized within 12 months of the date of acquisition. *** The fair value of the contingent consideration was estimated at the date of acquisition. At June 30, 2020, the contingent consideration has been settled at fair value in the amount of $0.5 million. The change in fair value has been recorded in the Condensed Consolidated Statement of Operations. Acquisitions – MeDiNova On May 23, 2019 a subsidiary of the Company, ICON Clinical Research (U.K.) Limited acquired a majority shareholding in MeDiNova, a site network with research sites in key markets in Europe and Africa. On March 9, 2020 ICON exercised its option to call the outstanding shares in the noncontrolling interest to take 100% ownership of MeDiNova. The acquisition further enhances ICON's patient recruitment capabilities in EMEA and complements ICON's existing site network in the US, PMG Research. Accounting for the acquisition of MeDiNova was finalized in the period ended June 30, 2020. The acquisition of MeDiNova has been accounted for as a business combination in accordance with ASC 805 ' Business Combinations' . The Company made an assessment of the fair value of assets acquired and liabilities assumed as at that date. The following table summarizes the Company’s fair values of the assets acquired and liabilities assumed: May 23, 2019 (in thousands) Cash & cash equivalents $ 7,719 Property, plant and equipment 670 Operating right of use assets 1,558 Goodwill * 81,760 Customer relationships ** 3,887 Order backlog ** 171 Patient database ** 2,542 Accounts receivable 3,488 Unbilled revenue 4,272 Other receivables 819 Prepayments and other current assets 406 Accounts payable (5,484) Unearned revenue (5,796) Other liabilities (6,860) Current lease liabilities (430) Non-current lease liabilities (1,128) Non-current deferred tax liability (1,345) Net assets acquired $ 86,249 Cash outflows $ 54,123 Working capital adjustment received (466) Redeemable noncontrolling interest *** 32,592 Total consideration $ 86,249 *Goodwill represents the acquisition of an established workforce and access to a broad site network in Europe and Africa. None of the goodwill recognized is expected to be deductible for income tax purposes. * *In finalizing the acquisition of MeDiNova in the twelve month period from acquisition, fair value adjustments were made which resulted in an increase in other liabilities ($1.6 million) and decreases in operating right of use assets ($0.3 million), current lease liabilities ($0.1 million), non-current lease liabilities ($0.3 million) and non-current deferred tax liability ($2.2 million). Cust omer relationship, order backlog and patient database assets were also finalized. ***The fair value of the redeemable noncontrolling interest on May 23, 2019 was $32.6 million wh ich was estimated by applying an income based approach. The valuation approach used was based on the future earnings of the Company times an appropriate earnings multiple. On March 9, 2020 ICON exercised its option to call the outstanding shares in the noncontrolling interest to take 100% ownership of MeDiNova. Effective from this date, the noncontrolling interest was derecognized and a liability was recognized, representing the assessment of the redemption value of the noncontrolling interest. This liability was settled on July 17, 2020 for $43.9 million. Acquisitions – MolecularMD Corp ("MMD") On January 25, 2019 a subsidiary of the Company, ICON Laboratory Services, Inc. acquired 100% of the share capital of MMD. MMD is a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The consideration on acquisition was $42.2 million. The acquisition of MMD has been accounted for as a business combination in accordance with ASC 805 ' Business Combinations' . The Company has made an assessment of the fair value of assets acquired and liabilities assumed as at that date. The following table summarizes the Company’s fair values of the assets acquired and liabilities assumed: January 25, 2019 (in thousands) Cash & cash equivalent $ 686 Property, plant and equipment 1,697 Operating right of use assets 2,866 Goodwill * 22,430 Customer relationships 10,708 Order backlog 2,787 Accounts receivable 3,100 Unbilled revenue 2,421 Other receivables 43 Prepayments and other current assets 908 Deferred tax asset 1,568 Accounts payable (1,280) Unearned revenue (540) Other liabilities (1,232) Current lease liabilities (699) Non-current lease liabilities (2,167) Non-current other liabilities (1,123) Net assets acquired $ 42,173 Cash outflows $ 42,349 Working capital adjustment received (176) Total consideration $ 42,173 *Goodwill represents the acquisition of an established workforce with experience in molecular diagnostic specialty laboratory services and commercialization of precision medicines in oncology. None of the goodwill recognized is expected to be deductible for income tax purposes. Accounting for the acquisition of MMD was finalized at December 31, 2019.

Restructuring

Restructuring	6 Months Ended
	Jun. 30, 2020
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring Restructuring charges A restructuring charge of $18.1 million was recognized during the three months ended June 30, 2020 under a restructuring plan adopted following a review of operations. The restructuring plan reflected resource rationalization across the busine ss to improve resource utilization, resulting in a charge of $11.4 million and office consolidation resulting in a charge for onerous lease obligation of $6.7 million, including the recognition of an impairment of right of use assets of $5.4 million (see note 8 - Operating Leases ) and provision for other related costs of $1.3 million. Details of the restructuring charge recognized in the three and six months ended June, 30, 2020 are as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) Restructuring charge $ 18,089 $ — $ 18,089 $ — Total $ 18,089 $ — $ 18,089 — Details of the movement in the restructuring charge recognized in the three and six months ended June, 30, 2020 are as follows: Workforce reductions Onerous Lease Total (in thousands) Initial restructuring charge recorded $ 11,391 $ 6,698 $ 18,089 Utilization (1,807) — (1,807) Provision at June 30, 2020 $ 9,584 $ 6,698 $ 16,282 Prior Period Restructuring charges A restructuring charge of $12.5 million was recognized during the year ended December 31, 2018 under a restructuring plan adopted following a review of operations. The restructuring plan reflected resource rationalization across the business to improve resource utilization, resulting in a charge of $9.7 million and office consolidation resulting in the recognition of an onerous lease obligation of $2.8 million. No additional charge was recorded during the six months ended June 30, 2020. Workforce reductions Onerous Lease Total (in thousands) Initial restructuring charge recorded $ 9,684 $ 2,806 $ 12,490 Utilization (5,399) (672) (6,071) Provision at December 31, 2018 $ 4,285 $ 2,134 $ 6,419 Utilization (3,554) (1,228) (4,782) Provision at December 31, 2019 $ 731 $ 906 $ 1,637 Utilization (430) (211) (641) Provision at June 30, 2020 $ 301 $ 695 $ 996 At June 30, 2020, $12.7 million is included within other liabilities and $4.6 million within non-current other liabilities.

Operating leases

Operating leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Operating leases	Operating leases Lease costs recorded under operating leases for the three and six months ended June 30, 2020 were as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Operating lease costs $ 7,768 $ 8,964 $ 15,857 $ 17,619 Income from sub-leases (246) (547) (514) (1,067) Net operating lease costs $ 7,522 $ 8,417 $ 15,343 $ 16,552 Of the total cost of $15.3 million incurred in the six months ended June 30, 2020 (June 30, 2019: $16.6 million), $14.0 million (June 30, 2019: $15.3 million) is recorded within selling, general and administration costs and $1.3 million (June 30, 2019: $1.3 million) is recorded within direct costs. During the three and six months ended June 30, 2020 and June 30, 2019, costs incurred by the Group related to variable lease payments was de minimis. Right-of-use assets obtained during the three and six months ended June 30, 2020 net of early termination options, now reasonably certain to be exercised, totaled $(1.4) million and $2.9 million, respectively (June 30, 2019: $4.9 million and $17.9 million respectively). In the three and six months ended June 30, 2020, office consolidations resulted in the recognition of an onerous lease obligation. The right-of-use assets related to these offices have been impaired to the extent they are considered onerous and a loss $5.4 million was recorded (see note 7 - Restructuring ). No impairment losses were recognized in the three and six months ended June 30, 2019. The weighted average remaining lease term and weighted-average discount rate at June 30, 2020 were 4.77 years and 2.66%, respectively. Future minimum lease payments under non-cancelable leases as of June 30, 2020 were as follows: Minimum rental payments (in thousands) June 30, 2020 Due within 1 year $ 25,095 Due between 1 and 5 years 55,632 Thereafter 12,369 Total future minimum lease payments 93,096 Lease imputed interest (6,027) Total $ 87,069 Operating lease liabilities are presented as current and non-current. Operating lease liabilities of $23.1 million have been included in other liabilities as at June 30, 2020 (June 30, 2019: $29.0 million).

Income taxes

Income taxes	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income taxes	Income taxes Income taxes recognized during the three and six months ended June 30, 2020 and June 30, 2019, comprise: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Provision for income taxes $ 8,671 $ 12,456 $ 21,261 $ 24,496 Tax impact of restructuring and other items (2,261) — (2,261) — Provision for income taxes $ 6,410 $ 12,456 $ 19,000 $ 24,496 As at June 30, 2020 the Company maintains a $19.3 million liability (December 31, 2019: $21.3 million) for unrecognized tax benefit, which is comprised of $18.9 million (December 31, 2019: $20.2 million) related to items generating unrecognized tax benefits and $0.4 million (December 31, 2019: $1.1 million) for interest and related penalties to such items. The Company recognizes interest accrued on unrecognized tax benefits as an additional income tax expense. The Company has analyzed the filing positions in all of the significant federal, state and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. The only periods subject to examination by the major tax jurisdictions where the Company does business are 2015 through 2019 tax years. The Company does not believe that the outcome of any examination will have a material impact on its financial statements.

Net income per ordinary share

Net income per ordinary share	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Net income per ordinary share	Net income per ordinary share Basic net income per ordinary share attributable to the Group has been computed by dividing net income available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net income per ordinary share is computed by adjusting the weighted average number of ordinary shares outstanding during the period for all potentially dilutive ordinary shares outstanding during the period and adjusting net income for any changes in income or loss that would result from the conversion of such potential ordinary shares. There is no difference in net income used for basic and diluted net income per ordinary share. Basic and diluted net income per ordinary share attributable to the Group includes the adjustment to reflect the accretion of the noncontrolling interest in MeDiNova to its redemption value. The reconciliation of the number of shares used in the computation of basic and diluted net income per ordinary share is as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 Weighted average number of ordinary shares outstanding for basic net income per ordinary share 52,570,104 53,957,446 52,959,229 53,901,427 Effect of dilutive share options outstanding 458,463 491,671 731,909 454,278 Weighted average number of ordinary shares outstanding for diluted net income per ordinary share 53,028,567 54,449,117 53,691,138 54,355,705 The reconciliation of net income attributable to the Group and net income attributable to the group (including NCI redemption amount) as used to calculate net income per ordinary share attributable to the Group is as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Net income attributable to the Group $ 47,760 $ 91,857 $ 139,456 $ 180,154 Noncontrolling interest adjustment to redemption amount — — (4,522) — Net income attributable to the Group (including NCI redemption adjustment) $ 47,760 $ 91,857 $ 134,934 $ 180,154 Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 Net income per Ordinary Share attributable to the Group (including NCI redemption adjustment): Basic $ 0.91 $ 1.70 $ 2.55 $ 3.34 Diluted $ 0.90 $ 1.69 $ 2.51 $ 3.31

Share-based awards

Share-based awards	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-based awards	Share-based awards Share Options On July 21, 2008, the Company adopted the Employee Share Option Plan 2008 (the “2008 Employee Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any employee, or any Director holding a salaried office or employment with the Company or a Subsidiary for the purchase of ordinary shares. On the same date, the Company also adopted the Consultants Share Option Plan 2008 (the “2008 Consultants Plan”), pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any consultant, adviser or non-executive Director retained by the Company or any Subsidiary for the purchase of ordinary shares. On February 14, 2017, both the 2008 Employee Plan and the 2008 Consultants Plan (together the “2008 Option Plans”) were amended and restated in order to increase the number of options that can be issued under the 2008 Consultants Plan from 0.4 million to 1.0 million and to extend the date for options to be granted under the 2008 Option Plans. An aggregate of 6.0 million ordinary shares have been reserved under the 2008 Employee Plan, as reduced by any shares issued or to be issued pursuant to options granted under the 2008 Consultants Plan, under which a limit of 1.0 million shares applies. Further, the maximum number of ordinary shares with respect to which options may be granted under the 2008 Employee Option Plan, during any calendar year to any employee shall be 0.4 million ordinary shares. There is no individual limit under the 2008 Consultants Plan. No options may be granted under the 2008 Option Plans after February 14, 2027. Each option granted under the 2008 Option Plans will be an employee stock option, or NSO, as described in Section 422 or 423 of the Internal Revenue Code. Each grant of an option under the 2008 Options Plans will be evidenced by a Stock Option Agreement between the optionee and the Company. The exercise price will be specified in each Stock Option Agreement, however option prices will not be less than 100% of the fair market value of an ordinary share on the date the option is granted. On January 17, 2003, the Company adopted the Share Option Plan 2003 (the “2003 Share Option Plan”) pursuant to which the Compensation and Organization Committee of the Board could grant options to officers and other employees of the Company or its subsidiaries for the purchase of ordinary shares. An aggregate of 6.0 million ordinary shares were reserved under the 2003 Share Option Plan; and, in no event could the number of ordinary shares issued pursuant to options awarded under this plan exceed 10% of the outstanding shares, as defined in the 2003 Share Option Plan, at the time of the grant, unless the Board expressly determined otherwise. Further, the maximum number of ordinary shares with respect to which options could be granted under the 2003 Share Option Plan during any calendar year to any employee was 0.4 million ordinary shares. The 2003 Share Option Plan expired on January 17, 2013. No new options may be granted under this plan. Share option awards are granted with an exercise price equal to the market price of the Company’s shares at date of grant. Prior to 2018, share options typically vest over a period of five years from date of grant and expire eight years from date of grant. Share options granted to non-executive directors during 2018 vest over 12 months and expire eight years from the date of grant. The maximum contractual term of options outstanding at June 30, 2020 is eight years. The following table summarizes option activity for the six months ended June 30, 2020: Options Weighted Weighted Weighted Outstanding at December 31, 2019 656,107 $ 87.80 $ 26.60 4.76 Granted 107,737 $ 159.83 $ 42.43 Exercised (40,199) $ 36.00 $ 13.03 Canceled/expired (4,420) $ 22.30 $ 9.72 Outstanding at June 30, 2020 719,225 $ 101.89 $ 29.84 5.00 Exercisable at June 30, 2020 378,063 $ 80.50 $ 24.12 3.90 The Company has outstanding options with fair values ranging from $11.58 to $46.72 per option or a weighted average fair value of $22.51 per option. The Company issues ordinary shares for all options exercised. The total amount of fully vested share options which remained outstanding at June 30, 2020 was 378,063. Fully vested share options at June 30, 2020 have an average remaining contractual term of 3.90 years, an average exercise price of $80.50 and a total intrinsic value of $33.3 million. The total intrinsic value of options exercised during the six months ended June 30, 2020 was $4.3 million (June 30, 2019: $19.3 million). The following table summarizes the movement in non-vested share options for the six months ended June 30, 2020: Options Weighted Average Weighted Average Non-vested outstanding at December 31, 2019 358,030 $ 103.68 $ 31.28 Granted 107,737 $ 159.83 $ 42.43 Vested (124,605) $ 92.25 $ 27.51 Forfeited — $ — $ — Non-vested outstanding at June 30, 2020 341,162 $ 125.59 $ 36.18 Fair value of Stock Options Assumptions The weighted average fair value of options granted during the six months ended June 30, 2020 and June 30, 2019 was calculated using the Black-Scholes option pricing model. The weighted average grant date fair values and assumptions used were as follows: Six Months Ended June 30, 2020 June 30, 2019 Weighted average grant date fair value $ 42.43 $ 43.43 Assumptions: Expected volatility 30 % 30 % Dividend yield — % — % Risk-free interest rate 0.57 % 2.55 % Expected life 5 years 5 years Expected volatility is based on the historical volatility of our common stock over a period equal to the expected term of the options; the expected life represents the weighted average period of time that options granted are expected to be outstanding given consideration to vesting schedules and our historical experience of past vesting and termination patterns. The risk-free rate is based on the U.S. government zero-coupon bonds yield curve in effect at time of the grant for periods corresponding with the expected life of the option. Restricted Share Units and Performance Share Units On April 23, 2013, the Company adopted the 2013 Employees Restricted Share Unit and Performance Share Unit Plan (the “2013 RSU Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any employee, or any Director holding a salaried office or employment with the Company, or a Subsidiary to receive an award under the plan. On May 11, 2015, the 2013 RSU Plan was amended and restated in order to increase the number of shares that can be issued under the RSU Plan by 2.5 million shares. Accordingly, an aggregate of 4.1 million ordinary shares have been reserved for issuance under the 2013 RSU Plan. The shares are awarded at par value and vest over a service period. Awards under the 2013 RSU Plan may be settled in cash or shares at the option of the Company. On April 30 2019, the Company approved the 2019 Consultants and Directors Restricted Share Unit Plan (the “2019 Consultants RSU Plan”), which was effective as of May 16, 2019, pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any consultant, adviser or non-executive Director retained by the Company, or a Subsidiary to receive an award under the plan. 250,000 ordinary shares have been reserved for issuance under the 2019 Consultants RSU Plan. The awards are at par value and vest over a service period. Awards granted to non-executive directors during 2019 and 2020 vest over twelve months. The Company has awarded RSUs and PSUs to certain key individuals of the Group. The following table summarizes RSU and PSU activity for the six months ended June 30, 2020: PSU RSU Outstanding at December 31, 2019 175,989 $ 110.79 1.04 389,900 $ 119.07 1.43 Granted 57,184 $ 165.30 125,756 $ 165.18 Shares vested (63,516) $ 83.92 (138,939) $ 98.20 Forfeited (197) $ 83.47 (16,994) $ 126.73 Outstanding at June 30, 2020 169,460 $ 137.53 1.64 359,723 $ 142.86 1.82 The fair value of PSUs vested for the six months ended June 30, 2020 totaled $5.3 million (full year 2019: $16.5 million). The fair value of RSUs vested for the six months ended June 30, 2020 totaled $13.6 million (full year 2019: $8.5 million). The PSUs vest based on service and specified EPS targets over the periods 2018 – 2020, 2019 – 2021 and 2020 – 2022. Depending on the amount of EPS from 2018 to 2022, up to an additional 78,645 PSUs may also be granted. Non-cash stock compensation expense Non-cash stock compensation expense for the three and six months ended June 30, 2020 and June 30, 2019 has been allocated as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Direct costs $ 2,353 $ 3,171 $ 4,188 $ 7,072 Selling, general and administrative 4,764 2,584 8,998 5,762 $ 7,117 $ 5,755 $ 13,186 $ 12,834 Total non-cash stock compensation expense not yet recognized at June 30, 2020 amounted to $61.1 million. The weighted average period over which this is expected to be recognized is 2.42 years.

Share capital

Share capital	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Share capital	Share capital The Company can acquire up to 10% of its outstanding ordinary shares (by way of redemption), in accordance with Irish law, the United States securities laws, and the Company’s constitutional documents through open market share acquisitions. On January 8, 2019, the Company commenced a share buyback program of up to 1.0 million ordinary shares which was completed during the year ended December 31, 2019 for total consideration of $141.6 million. On October 22 2019, the Company commenced a further share buyback program. At December 31, 2019 35,100 ordinary shares were redeemed for a total consideration of $5.3 million. During the six months ended June 30, 2020 1,235,218 ordinary shares were redeemed by the Company under this buyback program for a total consideration of $175.0 million. The buyback program gives a broker authority to acquire the Company’s ordinary shares from time to time on the open market in accordance with agreed terms and limitations. All ordinary shares that were redeemed under the buyback program were canceled in accordance with the Constitution of the Company and the nominal value of these shares transferred to an other undenominated capital reserve as required under Irish Company Law.

Business segment information

Business segment information	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Business segment information	Business segment information The Company determines and presents operating segments based on the information that is internally provided to the chief operating decision maker, the (‘CODM’) in accordance with ASC 280 'Segment Reporting' . The Company determined that the CODM was comprised of the Chief Executive Officer and the Chief Financial Officer. The Company determines and presents operating segments based on the information that is provided to the CODM. The Company operates as one single business segment, which is the provision of outsourced development services on a global basis to the pharmaceutical, biotechnology and medical devices industries. There have been no changes to the basis of segmentation or the measurement basis for the segment results in the period. The Company is a clinical research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. It specializes in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. The Company has the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and has the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. The Company has expanded predominately through internal growth together with a number of strategic acquisitions to enhance its expertise and capabilities in certain areas of the clinical development process. The Company is generally awarded projects based upon responses to requests for proposals received from companies in the pharmaceutical, biotechnology and medical device industries or work orders executed under our strategic partnership arrangements. Contracts with customers are generally entered into centrally, in most cases with ICON Clinical Research Limited (“ICON Ireland”), the Company’s principal operating subsidiary in Ireland. Revenues, which consist primarily of fees earned under these contracts, are allocated to individual entities within the Group, based on where the work is performed in accordance with the Company’s global transfer pricing model. ICON Ireland acts as the group entrepreneur under the Company’s global transfer pricing model given its role in the development and management of the group, its ownership of key intellectual property and customer relationships, its key role in the mitigation of risks faced by the group and its responsibility for maintaining the Company’s global network. ICON Ireland enters into the majority of the Company’s customer contracts. ICON Ireland remunerates other operating entities in the ICON Group on the basis of a guaranteed cost plus mark-up for the services they perform in each of their local territories. The cost plus mark-up for each ICON entity is established to ensure that each of ICON Ireland and the ICON entities that are involved in the conduct of services for customers, earn an appropriate arms-length return having regard to the assets owned, risks borne, and functions performed by each entity from these intercompany transactions. The cost plus mark up policy is reviewed annually to ensure that it is market appropriate. The geographic split of revenue disclosed for each region outside Ireland is the cost plus revenue attributable to these entities. The residual revenues of the Group, once each ICON entity has been paid its respective intercompany service fee, generally fall to be retained by ICON Ireland. As such, revenues and income from operations in Ireland are a function of this global transfer pricing model and comprise revenues of the Group after deducting the cost plus revenues attributable to the activities performed outside Ireland. The Company's areas of operation outside of Ireland include the United States, United Kingdom, Belgium, Bulgaria, France, Germany, Italy, Spain, Poland, Portugal, Czech Republic, Hungary, Israel, Latvia, Romania, Russia, Serbia, Sweden, The Netherlands, Turkey, Ukraine, Canada, Argentina, Brazil, Chile, Colombia, Mexico, Peru, India, China (including Hong Kong), Japan, Singapore, South Korea, The Philippines, Taiwan, Thailand, Australia, New Zealand and South Africa. The geographical distribution of the Company’s segment measures as at June 30, 2020 and December 31, 2019 and for the three and six months ended June 30, 2020 and June 30, 2019 is as follows: a) The distribution of revenue by geographical area was as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Ireland * $ 279,743 $ 310,477 $ 594,715 $ 608,960 Rest of Europe 89,387 94,192 191,818 184,637 U.S. 189,466 222,312 414,933 440,852 Rest of World 61,632 68,156 133,864 135,540 Total $ 620,228 $ 695,137 $ 1,335,330 $ 1,369,989 * All sales shown for Ireland are export sales. b) The distribution of income from operations including restructuring by geographical area was as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Ireland $ 38,655 $ 78,052 $ 112,590 $ 148,673 Rest of Europe 7,120 5,663 17,816 11,513 U.S. 9,377 16,300 23,268 33,407 Rest of World 1,797 6,075 9,566 14,443 Total $ 56,949 $ 106,090 $ 163,240 $ 208,036 c) The distribution of income from operations excluding restructuring by geographical area was as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Ireland $ 56,744 $ 78,052 $ 130,679 $ 148,673 Rest of Europe 7,120 5,663 17,816 $ 11,513 U.S. 9,377 16,300 23,268 $ 33,407 Rest of World 1,797 6,075 9,566 14,443 Total $ 75,038 $ 106,090 $ 181,329 $ 208,036 d) The distribution of long-lived assets (including right-of-use assets), net, by geographical area was as follows: June 30, 2020 December 31, 2019 (in thousands) Ireland $ 108,531 $ 110,522 Rest of Europe 33,377 41,970 U.S. 64,932 72,578 Rest of World 41,979 44,994 Total $ 248,819 $ 270,064 e) The distribution of depreciation, amortization and reduction in carrying value of the right-of-use assets by geographical area was as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Ireland $ 7,951 $ 7,026 $ 16,192 $ 14,916 Rest of Europe 3,672 3,615 7,487 7,052 U.S. 6,201 9,539 14,840 17,180 Rest of World 5,043 2,608 7,998 6,583 Total $ 22,867 $ 22,788 $ 46,517 $ 45,731 f) The distribution of total assets by geographical area was as follows: June 30, 2020 December 31, 2019 (in thousands) Ireland $ 1,340,307 $ 1,323,181 Rest of Europe 605,148 660,797 U.S. 735,370 755,271 Rest of World 177,895 168,263 Total $ 2,858,720 $ 2,907,512

Impact of change in accounting

Impact of change in accounting policies	6 Months Ended
	Jun. 30, 2020
Accounting Changes and Error Corrections [Abstract]
Impact of change in accounting policies	Impact of change in accounting policies ASC 326 Financial Instruments - Credit Losses ASU 2016-13 'Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments' (ASU 2016-13) was effective, and adopted by the Group, from January 1, 2020. Primarily, ASU 2016-13 introduces an expected loss methodology that is referred to as the current expected credit loss (CECL) methodology. The objectives of previous loss methodologies for instruments within the scope of this update generally delayed recognition of the full amount of credit losses until the loss was probable of occurring. Under ASU 2016-13, losses reflect an entity’s current estimate of all expected credit losses including, in addition to the consideration of past events and current conditions, as under the current guidance, incorporating the use of forecast information to provide more timely and accurate credit loss estimates. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. It also applies to off-balance sheet credit exposures not accounted as insurance (loan commitments, standby letters of credit, financial guarantees, and other similar instruments) and net investments in leases recognized by a lessor in accordance with ASC 842 on leases. In addition, ASC 326 changed the accounting for available-for-sale (AFS) debt securities to require credit losses to be presented as an allowance rather than as a write-down to align the income statement recognition of credit losses on AFS debt securities with the reporting period in which the changes occur. The Group adopted ASC 326 using the modified retrospective method. Under this transition method, the new standard is applied from January 1, 2020 without restatement of comparative period amounts. The adoption of ASC 326 does not have a material impact on the Group and there was no impact of adopting ASC 326 on opening balances at January 1, 2020.

Significant accounting polici_2

Significant accounting policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
New accounting pronouncements	Financial assets - credit losses On January 1, 2020, the Group adopted ASU 2016-13 'Measurement of Credit Losses on Financial Instruments (ASC 326)' , which significantly changes the way entities recognize impairment of many financial assets by requiring immediate recognition of estimated credit losses expected to occur over their remaining life. The update provides guidance on the measurement of credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. The amendment replaces the current incurred loss impairment approach with a methodology to reflect expected credit losses and requires consideration of a broader range of reasonable and supportable information to explain credit loss estimates. The Group adopted ASC 326 using the modified retrospective method for all in scope financial assets. Results for reporting periods beginning after January 1, 2020 are presented under ASC 326 while prior period amounts continue to be reported in accordance with previously applicable GAAP. The impact of transitioning to the new standard at January 1, 2020 was immaterial and no adjustment was recorded to retained earnings for the cumulative effect of adopting ASC 326. On transition to ASC 326, the Group has revised the methodology to calculate the allowance for credit losses. The Group's estimate of expected credit losses considers historical credit loss information that is adjusted, where necessary, for current conditions and reasonable and supportable forecasts. Historical credit loss experience provides the basis for the estimation of expected credit losses. The Group's receivables and unbilled services are predominantly due from large and mid-tier pharmaceutical and biotechnology companies that share similar risk characteristics. The Group monitors their portfolio of receivables and unbilled services for any deterioration in current or expected credit quality (for example, expected delinquency level), and adjusts the allowance for credit losses as required. Changes in the allowance for credit losses are recorded as a provision for (or reversal of) credit loss expense in the Consolidated Statement of Operations. Losses are charged against the allowance when management believes the uncollectibility of a previously provisioned amount is confirmed. Leases The new leasing standard ( ASC 842 'Leases' ) was effective and adopted by ICON from January 1, 2019. ASC 842 ' Leases ' supersedes the requirements in ASC 840 'Leases' and requires that lessees recognize rights and obligations from virtually all leases (other than leases that meet the definition of a short-term lease) on their balance sheets as right-of-use assets with corresponding lease liabilities. The ASU also provides additional guidance on how to classify leases and how to determine the lease term for accounting purposes. ICON adopted the new standard under the cumulative effect adjustment approach There was no impact of adopting ASC 842 on opening retained earnings at January 1, 2019.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	Revenue disaggregated by customer profile is as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Top client $ 74,932 $ 89,565 $ 156,199 $ 189,559 Clients 2-5 179,018 166,772 381,996 336,285 Clients 6-10 86,449 87,725 160,800 166,499 Clients 11-25 101,417 139,086 231,501 274,748 Other 178,412 211,989 404,834 402,898 Total $ 620,228 $ 695,137 $ 1,335,330 $ 1,369,989

Accounts receivable, unbilled_2

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities) (Tables)	6 Months Ended
	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Schedule of Contracts with Customers, Asset and Liabilities	Accounts receivables and unbilled revenue are as follows: June 30, 2020 December 31, 2019 (in thousands) Contract assets: Billed services (accounts receivable) $ 482,349 $ 535,088 Unbilled services (unbilled revenue) 410,397 422,769 Accounts receivable and unbilled revenue 892,746 957,857 Allowance for credit losses (9,329) — Allowance for doubtful debts — (7,380) Accounts receivable and unbilled revenue, net $ 883,417 $ 950,477 Unbilled services and unearned revenue or payments on account (contract assets and liabilities) were as follows: (in thousands, except percentages) June 30, 2020 December 31, 2019 $ Change % Change Unbilled services (unbilled revenue) $ 410,397 $ 422,769 $ (12,372) (2.9) % Unearned revenue (payments on account) (393,217) (366,988) (26,229) 7.1 % Net balance $ 17,180 $ 55,781 $ (38,601) (69.2) %

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Six Months Ended Year Ended June 30, 2020 December 31, 2019 (in thousands) Opening balance $ 883,170 $ 756,260 Current period acquisitions (Note 6) 27,304 126,932 Prior period acquisitions 123 — Foreign exchange movement (9,352) (22) Closing balance $ 901,245 $ 883,170

Business combinations (Tables)

Business combinations (Tables)	6 Months Ended
	Jun. 30, 2020
Business Combinations [Abstract]
Schedule of Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed	January 22, 2020 (in thousands) Cash & cash equivalents $ 10,170 Property, plant and equipment 45 Operating right of use assets 539 Goodwill * 27,304 Customer relationships ** 11,725 Order backlog ** 2,883 Accounts receivable 3,033 Prepayments and other current assets 158 Accounts payable (368) Unearned revenue (989) Other liabilities (2,315) Current lease liabilities (219) Non-current lease liabilities (320) Non-current deferred tax liability (4,090) Net assets acquired $ 47,556 Cash outflows $ 46,992 Working capital adjustment payable 564 Contingent consideration *** — Total consideration $ 47,556 * Goodwill represents the acquisition of an established workforce that specializes in medical device development and market access. None of the goodwill recognized is expected to be deductible for income tax purposes. ** The Company has made an estimate of separate intangible assets acquired, being customer relationships and order book assets. This assessment will be finalized within 12 months of the date of acquisition. *** The fair value of the contingent consideration was estimated at the date of acquisition. Depending on performance of the company, the total consideration could increase by a maximum of $6.7 million in contingent consideration. At June 30, 2020, the fair value of this contingent consideration payable to MedPass is $Nil. September 24, 2019 (in thousands) Cash & cash equivalents $ 3,292 Property, plant and equipment 564 Operating right of use assets 820 Goodwill * 22,865 Customer relationships ** 8,159 Order backlog ** 2,163 Accounts receivable 4,544 Unbilled revenue 186 Prepayments and other current assets 181 Other receivables 6 Accounts payable (799) Unearned revenue (2,411) Other liabilities (933) Current lease liabilities (289) Non-current lease liabilities (531) Net assets acquired $ 37,817 Cash outflows $ 34,976 Working capital adjustment paid 341 Contingent consideration *** 2,500 Total consideration $ 37,817 * Goodwill represents the acquisition of an established workforce and the capability to provide at-home trial services and site support solutions. The full amount of the goodwill recognized is expected to be deductible for income tax purposes. ** The Company has made an estimate of separate intangible assets acquired, being customer relationships and order book assets. The fair value of Symphony’s intangible assets has been measured provisionally, pending receipt of a final independent valuation. This assessment will be finalized within 12 months of the date of acquisition. *** The fair value of the contingent consideration was estimated at the date of acquisition. At June 30, 2020, the contingent consideration has been settled at fair value in the amount of $0.5 million. The change in fair value has been recorded in the Condensed Consolidated Statement of Operations. May 23, 2019 (in thousands) Cash & cash equivalents $ 7,719 Property, plant and equipment 670 Operating right of use assets 1,558 Goodwill * 81,760 Customer relationships ** 3,887 Order backlog ** 171 Patient database ** 2,542 Accounts receivable 3,488 Unbilled revenue 4,272 Other receivables 819 Prepayments and other current assets 406 Accounts payable (5,484) Unearned revenue (5,796) Other liabilities (6,860) Current lease liabilities (430) Non-current lease liabilities (1,128) Non-current deferred tax liability (1,345) Net assets acquired $ 86,249 Cash outflows $ 54,123 Working capital adjustment received (466) Redeemable noncontrolling interest *** 32,592 Total consideration $ 86,249 *Goodwill represents the acquisition of an established workforce and access to a broad site network in Europe and Africa. None of the goodwill recognized is expected to be deductible for income tax purposes. * *In finalizing the acquisition of MeDiNova in the twelve month period from acquisition, fair value adjustments were made which resulted in an increase in other liabilities ($1.6 million) and decreases in operating right of use assets ($0.3 million), current lease liabilities ($0.1 million), non-current lease liabilities ($0.3 million) and non-current deferred tax liability ($2.2 million). Cust omer relationship, order backlog and patient database assets were also finalized. ***The fair value of the redeemable noncontrolling interest on May 23, 2019 was $32.6 million wh ich was estimated by applying an income based approach. The valuation approach used was based on the future earnings of the Company times an appropriate earnings multiple. On March 9, 2020 ICON exercised its option to call the outstanding shares in the noncontrolling interest to take 100% ownership of MeDiNova. Effective from this date, the noncontrolling interest was derecognized and a liability was recognized, representing the assessment of the redemption value of the noncontrolling interest. This liability was settled on July 17, 2020 for $43.9 million. January 25, 2019 (in thousands) Cash & cash equivalent $ 686 Property, plant and equipment 1,697 Operating right of use assets 2,866 Goodwill * 22,430 Customer relationships 10,708 Order backlog 2,787 Accounts receivable 3,100 Unbilled revenue 2,421 Other receivables 43 Prepayments and other current assets 908 Deferred tax asset 1,568 Accounts payable (1,280) Unearned revenue (540) Other liabilities (1,232) Current lease liabilities (699) Non-current lease liabilities (2,167) Non-current other liabilities (1,123) Net assets acquired $ 42,173 Cash outflows $ 42,349 Working capital adjustment received (176) Total consideration $ 42,173 *Goodwill represents the acquisition of an established workforce with experience in molecular diagnostic specialty laboratory services and commercialization of precision medicines in oncology. None of the goodwill recognized is expected to be deductible for income tax purposes.

Restructuring (Tables)

Restructuring (Tables)	6 Months Ended
	Jun. 30, 2020
Restructuring and Related Activities [Abstract]
Restructuring charge	Details of the restructuring charge recognized in the three and six months ended June, 30, 2020 are as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) Restructuring charge $ 18,089 $ — $ 18,089 $ — Total $ 18,089 $ — $ 18,089 —
Details of movement in restructuring charge	Details of the movement in the restructuring charge recognized in the three and six months ended June, 30, 2020 are as follows: Workforce reductions Onerous Lease Total (in thousands) Initial restructuring charge recorded $ 11,391 $ 6,698 $ 18,089 Utilization (1,807) — (1,807) Provision at June 30, 2020 $ 9,584 $ 6,698 $ 16,282 Workforce reductions Onerous Lease Total (in thousands) Initial restructuring charge recorded $ 9,684 $ 2,806 $ 12,490 Utilization (5,399) (672) (6,071) Provision at December 31, 2018 $ 4,285 $ 2,134 $ 6,419 Utilization (3,554) (1,228) (4,782) Provision at December 31, 2019 $ 731 $ 906 $ 1,637 Utilization (430) (211) (641) Provision at June 30, 2020 $ 301 $ 695 $ 996

Operating leases (Tables)

Operating leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of Lease Costs	Lease costs recorded under operating leases for the three and six months ended June 30, 2020 were as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Operating lease costs $ 7,768 $ 8,964 $ 15,857 $ 17,619 Income from sub-leases (246) (547) (514) (1,067) Net operating lease costs $ 7,522 $ 8,417 $ 15,343 $ 16,552
Schedule of Operating Lease Maturity	Future minimum lease payments under non-cancelable leases as of June 30, 2020 were as follows: Minimum rental payments (in thousands) June 30, 2020 Due within 1 year $ 25,095 Due between 1 and 5 years 55,632 Thereafter 12,369 Total future minimum lease payments 93,096 Lease imputed interest (6,027) Total $ 87,069

Income taxes (Tables)

Income taxes (Tables)	6 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense	Income taxes recognized during the three and six months ended June 30, 2020 and June 30, 2019, comprise: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Provision for income taxes $ 8,671 $ 12,456 $ 21,261 $ 24,496 Tax impact of restructuring and other items (2,261) — (2,261) — Provision for income taxes $ 6,410 $ 12,456 $ 19,000 $ 24,496

Net income per ordinary share (

Net income per ordinary share (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The reconciliation of the number of shares used in the computation of basic and diluted net income per ordinary share is as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 Weighted average number of ordinary shares outstanding for basic net income per ordinary share 52,570,104 53,957,446 52,959,229 53,901,427 Effect of dilutive share options outstanding 458,463 491,671 731,909 454,278 Weighted average number of ordinary shares outstanding for diluted net income per ordinary share 53,028,567 54,449,117 53,691,138 54,355,705 The reconciliation of net income attributable to the Group and net income attributable to the group (including NCI redemption amount) as used to calculate net income per ordinary share attributable to the Group is as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Net income attributable to the Group $ 47,760 $ 91,857 $ 139,456 $ 180,154 Noncontrolling interest adjustment to redemption amount — — (4,522) — Net income attributable to the Group (including NCI redemption adjustment) $ 47,760 $ 91,857 $ 134,934 $ 180,154 Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 Net income per Ordinary Share attributable to the Group (including NCI redemption adjustment): Basic $ 0.91 $ 1.70 $ 2.55 $ 3.34 Diluted $ 0.90 $ 1.69 $ 2.51 $ 3.31

Share-based awards (Tables)

Share-based awards (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Share Option Activity	The following table summarizes option activity for the six months ended June 30, 2020: Options Weighted Weighted Weighted Outstanding at December 31, 2019 656,107 $ 87.80 $ 26.60 4.76 Granted 107,737 $ 159.83 $ 42.43 Exercised (40,199) $ 36.00 $ 13.03 Canceled/expired (4,420) $ 22.30 $ 9.72 Outstanding at June 30, 2020 719,225 $ 101.89 $ 29.84 5.00 Exercisable at June 30, 2020 378,063 $ 80.50 $ 24.12 3.90
Schedule of Movement in Non-vested Share Options	The following table summarizes the movement in non-vested share options for the six months ended June 30, 2020: Options Weighted Average Weighted Average Non-vested outstanding at December 31, 2019 358,030 $ 103.68 $ 31.28 Granted 107,737 $ 159.83 $ 42.43 Vested (124,605) $ 92.25 $ 27.51 Forfeited — $ — $ — Non-vested outstanding at June 30, 2020 341,162 $ 125.59 $ 36.18
Schedule of Weighted Average Fair Values and Assumptions Used	The weighted average grant date fair values and assumptions used were as follows: Six Months Ended June 30, 2020 June 30, 2019 Weighted average grant date fair value $ 42.43 $ 43.43 Assumptions: Expected volatility 30 % 30 % Dividend yield — % — % Risk-free interest rate 0.57 % 2.55 % Expected life 5 years 5 years
Schedule of RSU and PSU Activity	The following table summarizes RSU and PSU activity for the six months ended June 30, 2020: PSU RSU Outstanding at December 31, 2019 175,989 $ 110.79 1.04 389,900 $ 119.07 1.43 Granted 57,184 $ 165.30 125,756 $ 165.18 Shares vested (63,516) $ 83.92 (138,939) $ 98.20 Forfeited (197) $ 83.47 (16,994) $ 126.73 Outstanding at June 30, 2020 169,460 $ 137.53 1.64 359,723 $ 142.86 1.82
Schedule of Non-cash Stock Compensation Expense	Non-cash stock compensation expense for the three and six months ended June 30, 2020 and June 30, 2019 has been allocated as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Direct costs $ 2,353 $ 3,171 $ 4,188 $ 7,072 Selling, general and administrative 4,764 2,584 8,998 5,762 $ 7,117 $ 5,755 $ 13,186 $ 12,834

Business segment information (T

Business segment information (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Distribution of Revenue by Geographical Area	The distribution of revenue by geographical area was as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Ireland * $ 279,743 $ 310,477 $ 594,715 $ 608,960 Rest of Europe 89,387 94,192 191,818 184,637 U.S. 189,466 222,312 414,933 440,852 Rest of World 61,632 68,156 133,864 135,540 Total $ 620,228 $ 695,137 $ 1,335,330 $ 1,369,989
Distribution of income from operations by geographical area	The distribution of income from operations including restructuring by geographical area was as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Ireland $ 38,655 $ 78,052 $ 112,590 $ 148,673 Rest of Europe 7,120 5,663 17,816 11,513 U.S. 9,377 16,300 23,268 33,407 Rest of World 1,797 6,075 9,566 14,443 Total $ 56,949 $ 106,090 $ 163,240 $ 208,036 Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Ireland $ 56,744 $ 78,052 $ 130,679 $ 148,673 Rest of Europe 7,120 5,663 17,816 $ 11,513 U.S. 9,377 16,300 23,268 $ 33,407 Rest of World 1,797 6,075 9,566 14,443 Total $ 75,038 $ 106,090 $ 181,329 $ 208,036
Distribution of Long-lived Assets, Net, by Geographical Area	The distribution of long-lived assets (including right-of-use assets), net, by geographical area was as follows: June 30, 2020 December 31, 2019 (in thousands) Ireland $ 108,531 $ 110,522 Rest of Europe 33,377 41,970 U.S. 64,932 72,578 Rest of World 41,979 44,994 Total $ 248,819 $ 270,064
Distribution of Depreciation and Amortization by Geographical Area	The distribution of depreciation, amortization and reduction in carrying value of the right-of-use assets by geographical area was as follows: Three Months Ended Six Months Ended June 30, 2020 June 30, 2019 June 30, 2020 June 30, 2019 (in thousands) (in thousands) Ireland $ 7,951 $ 7,026 $ 16,192 $ 14,916 Rest of Europe 3,672 3,615 7,487 7,052 U.S. 6,201 9,539 14,840 17,180 Rest of World 5,043 2,608 7,998 6,583 Total $ 22,867 $ 22,788 $ 46,517 $ 45,731
Distribution of Total Assets by Geographical Area	The distribution of total assets by geographical area was as follows: June 30, 2020 December 31, 2019 (in thousands) Ireland $ 1,340,307 $ 1,323,181 Rest of Europe 605,148 660,797 U.S. 735,370 755,271 Rest of World 177,895 168,263 Total $ 2,858,720 $ 2,907,512

Significant accounting polici_3

Significant accounting policies (Details) - USD ($)	Jul. 17, 2020	Dec. 31, 2019	Jun. 30, 2020	Mar. 09, 2020	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounting Standards Update [Extensible List]		us-gaap:AccountingStandardsUpdate201602Member
Operating right-of-use assets		$ 104,977,000	$ 86,267,000
Operating lease, liability			87,069,000
Opening retained earnings		$ 1,618,055,000	1,578,483,000
Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible List]		us-gaap:AccountingStandardsUpdate201602CumulativeEffectPeriodOfAdoptionMember
MeDiNova
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Percentage of interest acquired				100.00%
MeDiNova | Subsequent Event
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Settlement of liability	$ 43,900,000
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating right-of-use assets					$ 106,500,000
Operating lease, liability					106,500,000
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Opening retained earnings		$ 1,110,226,000	$ 1,070,020,000
Retained Earnings | Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Opening retained earnings					$ 0

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 620,228	$ 695,137	$ 1,335,330	$ 1,369,989
Top client
Disaggregation of Revenue [Line Items]
Revenue	74,932	89,565	156,199	189,559
Clients 2-5
Disaggregation of Revenue [Line Items]
Revenue	179,018	166,772	381,996	336,285
Clients 6-10
Disaggregation of Revenue [Line Items]
Revenue	86,449	87,725	160,800	166,499
Clients 11-25
Disaggregation of Revenue [Line Items]
Revenue	101,417	139,086	231,501	274,748
Other
Disaggregation of Revenue [Line Items]
Revenue	$ 178,412	$ 211,989	$ 404,834	$ 402,898

Accounts receivable, unbilled_3

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities) - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Billed services (accounts receivable)	$ 482,349	$ 535,088
Unbilled services (unbilled revenue)	410,397	422,769
Accounts receivable and unbilled revenue	892,746	957,857
Allowance for credit losses/doubtful debts	(9,329)	(7,380)
Accounts receivable and unbilled revenue, net	883,417	950,477
Unearned revenue (payments on account)	(393,217)	(366,988)
Net balance	17,180	$ 55,781
Change in unbilled services (unbilled revenue)	(12,372)
Change in unearned revenue (payments on account)	(26,229)
Change in net balance	$ (38,601)
Change in unbilled services (unbilled revenue), percent	(2.90%)
Change in unearned revenue (payments on account), percent	7.10%
Change in net balance, percent	(69.20%)

Accounts receivable, unbilled_4

Accounts receivable, unbilled revenue (contract assets) and unearned revenue or payments on account (contract liabilities) - Revenue Remaining Performance Obligations (Details) $ in Billions	Jun. 30, 2020USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation	$ 5.7
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, percent	43.00%
Revenue, remaining performance obligation, expected timing of satisfaction, period	12 months

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Goodwill [Roll Forward]
Opening balance	$ 883,170	$ 756,260
Current period acquisitions (Note 6)	27,304	126,932
Prior period acquisitions	123	0
Foreign exchange movement	(9,352)	(22)
Closing balance	$ 901,245	$ 883,170

Business combinations (Details)

Business combinations (Details) - USD ($)	Jul. 17, 2020	Jan. 22, 2020	Sep. 24, 2019	May 23, 2019	Jan. 25, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Mar. 09, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill						$ 901,245,000		$ 901,245,000		$ 883,170,000	$ 756,260,000
Cash outflows						47,367,000	$ 81,631,000
Medpass
Business Acquisition [Line Items]
Percentage of share capital acquired		100.00%
Cash & cash equivalents		$ 10,170,000
Property, plant and equipment		45,000
Operating right of use assets		539,000
Goodwill		27,304,000
Accounts receivable		3,033,000
Prepayments and other current assets		158,000
Accounts payable		(368,000)
Unearned revenue		(989,000)
Other liabilities		(2,315,000)
Current lease liabilities		(219,000)
Non-current lease liabilities		(320,000)
Non-current deferred tax liability		(4,090,000)
Net assets acquired		47,556,000
Cash outflows		46,992,000
Working capital adjustments (decrease) increase		564,000
Contingent consideration		0				0		0
Total consideration		47,556,000
Goodwill expected to be tax deductible		0
Contingent consideration, maximum amount		6,700,000
Symphony
Business Acquisition [Line Items]
Percentage of share capital acquired			100.00%
Cash & cash equivalents			$ 3,292,000
Property, plant and equipment			564,000
Operating right of use assets			820,000
Goodwill			22,865,000
Accounts receivable			4,544,000
Unbilled revenue			186,000
Other receivables			6,000
Prepayments and other current assets			181,000
Accounts payable			(799,000)
Unearned revenue			(2,411,000)
Other liabilities			(933,000)
Current lease liabilities			(289,000)
Non-current lease liabilities			(531,000)
Net assets acquired			37,817,000
Cash outflows			34,976,000
Working capital adjustments (decrease) increase			341,000
Contingent consideration			2,500,000			$ 500,000		500,000
Total consideration			37,817,000
MeDiNova
Business Acquisition [Line Items]
Percentage of interest acquired									100.00%
Cash & cash equivalents				$ 7,719,000
Property, plant and equipment				670,000
Operating right of use assets				1,558,000
Goodwill				81,760,000
Accounts receivable				3,488,000
Unbilled revenue				4,272,000
Other receivables				819,000
Prepayments and other current assets				406,000
Accounts payable				(5,484,000)
Unearned revenue				(5,796,000)
Other liabilities				(6,860,000)
Current lease liabilities				(430,000)
Non-current lease liabilities				(1,128,000)
Non-current deferred tax liability				(1,345,000)
Net assets acquired				86,249,000
Cash outflows				54,123,000
Working capital adjustments (decrease) increase				(466,000)
Redeemable noncontrolling interest				32,592,000
Total consideration				86,249,000
Goodwill expected to be tax deductible				0
Business combination fair value adjustment increase to other liabilities								1,600,000
Business combinations fair value adjustments decrease to operating right of use assets								300,000
Business combination fair value adjustments decrease to current lease liabilities								100,000
Business combinations fair value adjustments decrease to non-current lease liabilities								300,000
Business combinations fair value adjustments decrease to non-current deferred tax liability								$ 2,200,000
MeDiNova | Subsequent Event
Business Acquisition [Line Items]
Settlement of liability	$ 43,900,000
MMD
Business Acquisition [Line Items]
Percentage of share capital acquired					100.00%
Cash & cash equivalents					$ 686,000
Property, plant and equipment					1,697,000
Operating right of use assets					2,866,000
Goodwill					22,430,000
Accounts receivable					3,100,000
Unbilled revenue					2,421,000
Other receivables					43,000
Prepayments and other current assets					908,000
Deferred tax asset					1,568,000
Accounts payable					(1,280,000)
Unearned revenue					(540,000)
Other liabilities					(1,232,000)
Current lease liabilities					(699,000)
Non-current lease liabilities					(2,167,000)
Non-current other liabilities					(1,123,000)
Net assets acquired					42,173,000
Cash outflows					42,349,000
Working capital adjustments (decrease) increase					(176,000)
Total consideration					42,173,000
Goodwill expected to be tax deductible					0
Customer Relationships | Medpass
Business Acquisition [Line Items]
Customer relationships		11,725,000
Customer Relationships | Symphony
Business Acquisition [Line Items]
Customer relationships			8,159,000
Customer Relationships | MeDiNova
Business Acquisition [Line Items]
Customer relationships				3,887,000
Customer Relationships | MMD
Business Acquisition [Line Items]
Customer relationships					10,708,000
Order backlog | Medpass
Business Acquisition [Line Items]
Customer relationships		$ 2,883,000
Order backlog | Symphony
Business Acquisition [Line Items]
Customer relationships			$ 2,163,000
Order backlog | MeDiNova
Business Acquisition [Line Items]
Customer relationships				171,000
Order backlog | MMD
Business Acquisition [Line Items]
Customer relationships					$ 2,787,000
Patient database | MeDiNova
Business Acquisition [Line Items]
Customer relationships				$ 2,542,000

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 18,089,000	$ 0	$ 18,089,000	$ 0
Impairment of right-of-use assets			5,411,000	0
Other liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, current	12,700,000		12,700,000
Non-current other liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, noncurrent	4,600,000		4,600,000
Resource rationalization, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring charge	18,089,000	$ 0	18,089,000	$ 0
Impairment of right-of-use assets	5,400,000
Resource rationalization, 2020 | Workforce reductions
Restructuring Cost and Reserve [Line Items]
Restructuring charge	11,391,000		11,391,000
Resource rationalization, 2020 | Onerous Lease
Restructuring Cost and Reserve [Line Items]
Restructuring charge	6,698,000		6,698,000
Resource rationalization, 2020 | Other restructuring
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 1,300,000
Resource rationalizations 2018
Restructuring Cost and Reserve [Line Items]
Restructuring charge			$ 0		$ 12,490,000
Resource rationalizations 2018 | Workforce reductions
Restructuring Cost and Reserve [Line Items]
Restructuring charge					9,684,000
Resource rationalizations 2018 | Onerous Lease
Restructuring Cost and Reserve [Line Items]
Restructuring charge					$ 2,806,000

Restructuring - Rollforward Act

Restructuring - Rollforward Activity (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Restructuring Reserve [Roll Forward]
Restructuring charge	$ 18,089,000	$ 0	$ 18,089,000	$ 0
Resource rationalization, 2020
Restructuring Reserve [Roll Forward]
Restructuring charge	18,089,000	$ 0	18,089,000	0
Utilization	(1,807,000)		(1,807,000)
Provision, ending balance	16,282,000		16,282,000
Resource rationalization, 2020 | Workforce reductions
Restructuring Reserve [Roll Forward]
Restructuring charge	11,391,000		11,391,000
Utilization	(1,807,000)		(1,807,000)
Provision, ending balance	9,584,000		9,584,000
Resource rationalization, 2020 | Onerous Lease
Restructuring Reserve [Roll Forward]
Restructuring charge	6,698,000		6,698,000
Utilization	0		0
Provision, ending balance	6,698,000		6,698,000
Resource rationalizations 2018
Restructuring Reserve [Roll Forward]
Restructuring charge			0			$ 12,490,000
Provision, beginning balance			1,637,000	6,419,000	$ 6,419,000
Utilization			(641,000)		(4,782,000)	(6,071,000)
Provision, ending balance	996,000		996,000		1,637,000	6,419,000
Resource rationalizations 2018 | Workforce reductions
Restructuring Reserve [Roll Forward]
Restructuring charge						9,684,000
Provision, beginning balance			731,000	4,285,000	4,285,000
Utilization			(430,000)		(3,554,000)	(5,399,000)
Provision, ending balance	301,000		301,000		731,000	4,285,000
Resource rationalizations 2018 | Onerous Lease
Restructuring Reserve [Roll Forward]
Restructuring charge						2,806,000
Provision, beginning balance			906,000	$ 2,134,000	2,134,000
Utilization			(211,000)		(1,228,000)	(672,000)
Provision, ending balance	$ 695,000		$ 695,000		$ 906,000	$ 2,134,000

Operating leases - Lease Costs

Operating leases - Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating lease costs	$ 7,768	$ 8,964	$ 15,857	$ 17,619
Income from sub-leases	(246)	(547)	(514)	(1,067)
Net operating lease costs	$ 7,522	$ 8,417	$ 15,343	$ 16,552

Operating leases - Narrative (D

Operating leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Lessee, Lease, Description [Line Items]
Total lease cost	$ 7,522	$ 8,417	$ 15,343	$ 16,552
Right-of-use assets obtained in exchange for lease obligations	$ (1,400)	4,900	2,900	17,900
Impairment of right-of-use assets			$ 5,411	0
Weighted average remaining lease term (in years)	4 years 9 months 7 days		4 years 9 months 7 days
Weighted average discount rate	2.66%		2.66%
Other liabilities
Lessee, Lease, Description [Line Items]
Operating lease liabilities	$ 23,100	$ 29,000	$ 23,100	29,000
Selling, general and administration costs
Lessee, Lease, Description [Line Items]
Total lease cost			14,000	15,300
Direct costs
Lessee, Lease, Description [Line Items]
Total lease cost			$ 1,300	$ 1,300

Operating leases - Operating Le

Operating leases - Operating Lease Maturity (Details) $ in Thousands	Jun. 30, 2020USD ($)
Leases [Abstract]
Due within 1 year	$ 25,095
Due between 1 and 5 years	55,632
Thereafter	12,369
Total future minimum lease payments	93,096
Lease imputed interest	(6,027)
Total	$ 87,069

Income taxes - Income Taxes Rec

Income taxes - Income Taxes Recognized During Period (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 8,671	$ 12,456	$ 21,261	$ 24,496
Tax impact of restructuring and other items	(2,261)	0	(2,261)	0
Provision for income taxes	$ 6,410	$ 12,456	$ 19,000	$ 24,496

Income taxes - Narrative (Detai

Income taxes - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Liability for unrecognized tax benefit	$ 19.3	$ 21.3
Items generating unrecognized tax benefits	18.9	20.2
Interest and related penalties	$ 0.4	$ 1.1

Net income per ordinary share -

Net income per ordinary share - Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Weighted average number of ordinary shares outstanding for basic net income per ordinary share (in shares)	52,570,104	53,957,446	52,959,229	53,901,427
Effect of dilutive share options outstanding (in shares)	458,463	491,671	731,909	454,278
Weighted average number of ordinary shares outstanding for diluted net income per ordinary share (in shares)	53,028,567	54,449,117	53,691,138	54,355,705

Net income per ordinary share_2

Net income per ordinary share - Reconciliation of Net Income Attributable to the Group and Net Income Attributable To the Group (Including NCI Redemption Amount) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Earnings Per Share [Abstract]
Net income attributable to the group	$ 47,760	$ 91,857	$ 139,456	$ 180,154
Noncontrolling interest adjustment to redemption amount	0	0	(4,522)	0
Net income attributable to the Group (including NCI redemption adjustment)	$ 47,760	$ 91,857	$ 134,934	$ 180,154
Net income per Ordinary Share attributable to the Group (including NCI redemption adjustment):
Basic (USD per share)	$ 0.91	$ 1.70	$ 2.55	$ 3.34
Diluted (USD per share)	$ 0.90	$ 1.69	$ 2.51	$ 3.31

Share-based awards - Narrative

Share-based awards - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	Feb. 14, 2017	May 11, 2015	Jan. 17, 2003	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	May 16, 2019	Feb. 13, 2017
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Non-cash stock compensation expense not yet recognized				$ 61.1
Unrecognized stock-based compensation expense, weighted average period				2 years 5 months 1 day
Consultants Stock Plan, 2008 Plan
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Ordinary shares which have been reserved for issuance (in shares)	1,000,000							400,000
Limit of shares issued or to be issued pursuant to options granted (in shares)	1,000,000
Employee Stock Plan, 2008 Plan
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Ordinary shares which have been reserved for issuance (in shares)	6,000,000
Maximum number of shares per employee (in shares)	400,000
Option Plans 2008 | Minimum
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Percentage of option price for fair value of ordinary share	100.00%
Employee Stock Plan, 2003 Plan
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Ordinary shares which have been reserved for issuance (in shares)			6,000,000
Maximum number of shares per employee (in shares)			400,000
Maximum number of award as percentage of shares outstanding			10.00%
Employee Stock Option
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Weighted average contractual term of options outstanding				5 years		4 years 9 months 3 days
Weighted average fair value per option (USD per share)				$ 22.51
Exercisable - number of shares (in shares)				378,063
Exercisable - weighted average remaining contractual life				3 years 10 months 24 days
Exercisable - weighted average exercise price (USD per share)				$ 80.50
Fully vested total intrinsic value				$ 33.3
Intrinsic value of option exercised				$ 4.3	$ 19.3
Employee Stock Option | Minimum
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Options outstanding fair value (USD per share)				$ 11.58
Employee Stock Option | Maximum
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Weighted average contractual term of options outstanding				8 years
Options outstanding fair value (USD per share)				$ 46.72
Restricted Stock Units 2013
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Ordinary shares which have been reserved for issuance (in shares)		4,100,000
Ordinary shares which have been reserved for issuance (in shares)		2,500,000
Consultants Restricted Stock Units 2019
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Ordinary shares which have been reserved for issuance (in shares)							250,000
Performance Share Unit (PSUs)
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Fair value of stock units vested				$ 5.3		$ 16.5
Restricted Stock Units (RSUs)
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Fair value of stock units vested				$ 13.6		$ 8.5
PSUs Based on Service and EPS Targets | Maximum
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Stock units to be granted (in shares)				78,645
Award Date, All years excluding 2018 | Employee Stock Option
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Shares vesting period				5 years
Shares expiration period				8 years
Non-executive directors | Consultants Restricted Stock Units 2019
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Shares vesting period				12 months
Non-executive directors | Award Date, 2018 | Employee Stock Option
Compensation Related Costs Share Based Payments Disclosure [Line Items]
Shares vesting period				12 months
Shares expiration period				8 years

Share-based awards - Summary of

Share-based awards - Summary of Stock Option Activity (Details) - Employee Stock Option - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Options Outstanding Number of Shares
Outstanding at beginning of period (in shares)	656,107
Granted (in shares)	107,737
Exercised (in shares)	(40,199)
Canceled/expired (in shares)	(4,420)
Outstanding at end of period (in shares)	719,225		656,107
Exercisable at end of period (in shares)	378,063
Weighted Average Exercise Price
Outstanding at beginning of period (USD per share)	$ 87.80
Granted (USD per share)	159.83
Exercised (USD per share)	36
Canceled/expired (USD per share)	22.30
Outstanding at end of period (USD per share)	101.89		$ 87.80
Exercisable at end of period (USD per share)	80.50
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (USD per share)	26.60
Granted (USD per share)	42.43	$ 43.43
Exercised (USD per share)	13.03
Canceled/expired (USD per share)	9.72
Outstanding at end of period (USD per share)	29.84		$ 26.60
Exercisable at end of period (USD per share)	$ 24.12
Weighted Average Remaining Contractual Life
Outstanding at end of period (in years)	5 years		4 years 9 months 3 days
Exercisable at end of period (in years)	3 years 10 months 24 days

Share-based awards - Summary _2

Share-based awards - Summary of Movement in Non-Vested Share Options (Details) - Employee Stock Option - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Options Outstanding Number of Shares
Non-vested outstanding at beginning of period (in shares)	358,030
Granted (in shares)	107,737
Vested (in shares)	(124,605)
Forfeited (in shares)	0
Non-vested outstanding at end of period (in shares)	341,162
Weighted Average Exercise Price
Non-vested outstanding at beginning of period (USD per share)	$ 103.68
Granted (USD per share)	159.83
Vested (USD per share)	92.25
Forfeited (USD per share)	0
Non-vested outstanding at end of period (USD per share)	125.59
Weighted Average Grant Date Fair Value
Non-vested outstanding at beginning of period (USD per share)	31.28
Granted (USD per share)	42.43	$ 43.43
Vested (USD per share)	27.51
Forfeited (USD per share)	0
Non-vested outstanding at end of period (USD per share)	$ 36.18

Share-based awards - Schedule o

Share-based awards - Schedule of Weighted Average Fair Values and Assumptions Used (Details) - Employee Stock Option - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 42.43	$ 43.43
Assumptions:
Expected volatility	30.00%	30.00%
Dividend yield	0.00%	0.00%
Risk-free interest rate	0.57%	2.55%
Expected life	5 years	5 years

Share-based awards - Summary _3

Share-based awards - Summary of RSU and PSU Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Performance Share Unit (PSUs)
Outstanding Number of Shares
Outstanding at beginning of period (in shares)	175,989
Granted (in shares)	57,184
Shares vested (in shares)	(63,516)
Forfeited (in shares)	(197)
Outstanding at end of period (in shares)	169,460	175,989
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (USD per share)	$ 110.79
Granted (USD per share)	165.30
Shares vested (USD per share)	83.92
Forfeited (USD per share)	83.47
Outstanding at end of period (USD per share)	$ 137.53	$ 110.79
Weighted Average Remaining Contractual Life
Outstanding at end of period (in years)	1 year 7 months 20 days	1 year 14 days
Restricted Stock Units (RSUs)
Outstanding Number of Shares
Outstanding at beginning of period (in shares)	389,900
Granted (in shares)	125,756
Shares vested (in shares)	(138,939)
Forfeited (in shares)	(16,994)
Outstanding at end of period (in shares)	359,723	389,900
Weighted Average Grant Date Fair Value
Outstanding at beginning of period (USD per share)	$ 119.07
Granted (USD per share)	165.18
Shares vested (USD per share)	98.20
Forfeited (USD per share)	126.73
Outstanding at end of period (USD per share)	$ 142.86	$ 119.07
Weighted Average Remaining Contractual Life
Outstanding at end of period (in years)	1 year 9 months 25 days	1 year 5 months 4 days

Share-based awards - Schedule_2

Share-based awards - Schedule of Non-cash Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 7,117	$ 5,755	$ 13,186	$ 12,834
Direct costs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	2,353	3,171	4,188	7,072
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock compensation expense	$ 4,764	$ 2,584	$ 8,998	$ 5,762

Share capital (Details)

Share capital (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jun. 30, 2020	Dec. 31, 2019	Jan. 08, 2019
Equity, Class of Treasury Stock [Line Items]
Shares redeemed, value		$ 175,000
Buyback Program
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, number of shares authorized to be repurchased (in shares)				1,000,000
Shares redeemed, value	$ 5,300	$ 175,000	$ 141,600
Shares redeemed (in shares)	35,100	1,235,218
Buyback Program | Maximum
Equity, Class of Treasury Stock [Line Items]
Share repurchase program, authorized percentage		10.00%

Business segment information -

Business segment information - Narrative (Details)	6 Months Ended
	Jun. 30, 2020segment
Segment Reporting [Abstract]
Number of operating segments	1

Business segment information _2

Business segment information - Distribution of Revenue by Geographical Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Revenue	$ 620,228	$ 695,137	$ 1,335,330	$ 1,369,989
Ireland
Segment Reporting Information [Line Items]
Revenue	279,743	310,477	594,715	608,960
Rest of Europe
Segment Reporting Information [Line Items]
Revenue	89,387	94,192	191,818	184,637
U.S.
Segment Reporting Information [Line Items]
Revenue	189,466	222,312	414,933	440,852
Rest of World
Segment Reporting Information [Line Items]
Revenue	$ 61,632	$ 68,156	$ 133,864	$ 135,540

Business segment information _3

Business segment information - Distribution of Income from Operations, Including Restructuring, by Geographical Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Income from operations, including restructuring	$ 56,949	$ 106,090	$ 163,240	$ 208,036
Ireland
Segment Reporting Information [Line Items]
Income from operations, including restructuring	38,655	78,052	112,590	148,673
Rest of Europe
Segment Reporting Information [Line Items]
Income from operations, including restructuring	7,120	5,663	17,816	11,513
U.S.
Segment Reporting Information [Line Items]
Income from operations, including restructuring	9,377	16,300	23,268	33,407
Rest of World
Segment Reporting Information [Line Items]
Income from operations, including restructuring	$ 1,797	$ 6,075	$ 9,566	$ 14,443

Business segment information _4

Business segment information - Distribution of Income from Operations, Excluding Restructuring by Geographical Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Operating income (loss) excluding restructuring	$ 75,038	$ 106,090	$ 181,329	$ 208,036
Ireland
Segment Reporting Information [Line Items]
Operating income (loss) excluding restructuring	56,744	78,052	130,679	148,673
Rest of Europe
Segment Reporting Information [Line Items]
Operating income (loss) excluding restructuring	7,120	5,663	17,816	11,513
U.S.
Segment Reporting Information [Line Items]
Operating income (loss) excluding restructuring	9,377	16,300	23,268	33,407
Rest of World
Segment Reporting Information [Line Items]
Operating income (loss) excluding restructuring	$ 1,797	$ 6,075	$ 9,566	$ 14,443

Business segment information _5

Business segment information - Distribution of Long-lived Assets, Net, by Geographical Area (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Long-lived assets, net	$ 248,819	$ 270,064
Ireland
Segment Reporting Information [Line Items]
Long-lived assets, net	108,531	110,522
Rest of Europe
Segment Reporting Information [Line Items]
Long-lived assets, net	33,377	41,970
U.S.
Segment Reporting Information [Line Items]
Long-lived assets, net	64,932	72,578
Rest of World
Segment Reporting Information [Line Items]
Long-lived assets, net	$ 41,979	$ 44,994

Business segment information _6

Business segment information - Distribution of Depreciation and Amortization by Geographical Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Depreciation, amortization and reduction in carrying value of right-of-use assets	$ 22,867	$ 22,788	$ 46,517	$ 45,731
Ireland
Segment Reporting Information [Line Items]
Depreciation, amortization and reduction in carrying value of right-of-use assets	7,951	7,026	16,192	14,916
Rest of Europe
Segment Reporting Information [Line Items]
Depreciation, amortization and reduction in carrying value of right-of-use assets	3,672	3,615	7,487	7,052
U.S.
Segment Reporting Information [Line Items]
Depreciation, amortization and reduction in carrying value of right-of-use assets	6,201	9,539	14,840	17,180
Rest of World
Segment Reporting Information [Line Items]
Depreciation, amortization and reduction in carrying value of right-of-use assets	$ 5,043	$ 2,608	$ 7,998	$ 6,583

Business segment information _7

Business segment information - Distribution of Total Assets by Geographical Area (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Assets	$ 2,858,720	$ 2,907,512
Ireland
Segment Reporting Information [Line Items]
Assets	1,340,307	1,323,181
Rest of Europe
Segment Reporting Information [Line Items]
Assets	605,148	660,797
U.S.
Segment Reporting Information [Line Items]
Assets	735,370	755,271
Rest of World
Segment Reporting Information [Line Items]
Assets	$ 177,895	$ 168,263